Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors

• Status: Completed
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the Maximum Tolerated Dose and dose limiting toxicity of gimatecan administered orally in patients with advanced solid tumors

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Camptothecin

Criteria

Inclusion criteria:

• Advanced or metastatic cancer

• 18 years and above

Exclusion criteria:

• Previous treatment with 4 or more cycles of carboplatin;

• Previous treatment with 2 or more courses of nitrosourea or mitomycin;

• Previous radiation therapy greater than or equal to 25% of the hematopoietic reserve;

• Severe and/or uncontrolled medical conditions

Other protocol-defined inclusion/exclusion criteria may apply